Daratumumab plus lenalidomide and dexamethasone <i>versus</i> lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX
Meletios Α. Dimopoulos(National and Kapodistrian University of Athens), Jesús F. San Miguel(Clinica Universidad de Navarra), Andrew R. Belch(University of Alberta), Darrell White(Dalhousie University), Lotfi Benboubker(Centre Hospitalier Universitaire de Tours), Gordon Cook(Leeds Teaching Hospitals NHS Trust), Merav Leiba(Sheba Medical Center), James Morton(Cancer Council Queensland), P. Joy Ho(Royal Prince Alfred Hospital), Kihyun Kım(Samsung Medical Center), Naoki Takezako(National Disaster Medical Center), Philippe Moreau, Jonathan L. Kaufman(Emory University), Heather J. Sutherland(University of British Columbia), Marc Lalancette(Université Laval), Hila Magen(Rabin Medical Center), Shinsuke Iida(Nagoya City University), Jin Seok Kim(Yonsei University), H. Miles Prince(Peter MacCallum Cancer Centre), Tara Cochrane(Gold Coast Hospital), Albert Oriol(Institut Català d'Oncologia), Nizar J. Bahlis(University of Calgary), Ajai Chari(Icahn School of Medicine at Mount Sinai), Lisa O’Rourke(Janssen (United States)), Kaida Wu(Janssen (United States)), Jordan M. Schecter(Janssen (United States)), Tineke Casneuf(Janssen (Belgium)), Christopher Chiu(Janssen (United States)), David Soong(Janssen (United States)), A. Kate Sasser(Genmab (United States)), Nushmia Z. Khokhar(Janssen (United States)), Hervé Avet‐Loiseau(Institut universitaire du cancer de Toulouse Oncopole), Saad Z. Usmani(Levine Cancer Institute)
Cited by 210Open Access
Abstract
In the POLLUX study, daratumumab plus lenalidomide/dexamethasone significantly reduced risk of progression/death versus lenalidomide/dexamethasone alone in relapsed/refractory multiple myeloma. We provide one additional year of follow up and include the effect on minimal residual disease and in clinically relevant subgroups. After 25.4 months of follow up, daratumumab plus lenalidomide/dexamethasone prolonged progression-free survival versus lenalidomide/dexamethasone alone (median not reached vs. 17.5 months; hazard ratio, 0.41; 95% confidence interval, 0.31-0.53; P
Related Papers
No related papers found
Powered by citation graph analysis